Lupin gets target hike from Nomura to Rs 1,949 on growth potential in US products Nomura suggests that the launch of US products and stringent cost control measures could exceed current earnings estimates. Additionally, Lupin has potential limited competition opportunities in FY25 with products like gOracea, gMyrbetriq, and gSlynd, pending a favorable verdict.
MARKET VIEW
OUTLOOK
SECTORS
STRATEGY
VIEW
PERSONAL FINANCE
INSURANCE
INVEST
MUTUAL FUND
GENERAL